189 related articles for article (PubMed ID: 9682344)
21. Enhanced production of enveloped viruses in BST-2-deficient cell lines.
Yi E; Oh J; Giao NQ; Oh S; Park SH
Biotechnol Bioeng; 2017 Oct; 114(10):2289-2297. PubMed ID: 28498621
[TBL] [Abstract][Full Text] [Related]
22. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
23. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
Wu SC; Liu CC; Lian WC
Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
[TBL] [Abstract][Full Text] [Related]
24. Clinical development of a Vero cell culture-derived seasonal influenza vaccine.
Ehrlich HJ; Berezuk G; Fritsch S; Aichinger G; Singer J; Portsmouth D; Hart MK; El-Amin W; Kistner O; Barrett PN
Vaccine; 2012 Jun; 30(29):4377-86. PubMed ID: 22172502
[TBL] [Abstract][Full Text] [Related]
25. Humoral and cell-mediated immunity to vero cell-derived influenza vaccine.
Brühl P; Kerschbaum A; Kistner O; Barrett N; Dorner F; Gerencer M
Vaccine; 2000 Dec; 19(9-10):1149-58. PubMed ID: 11137251
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs.
Katz JM; Webster RG
J Infect Dis; 1989 Aug; 160(2):191-8. PubMed ID: 2760480
[TBL] [Abstract][Full Text] [Related]
27. Plaque purification as a method to mitigate the risk of adventitious-agent contamination in influenza vaccine virus seeds.
Murata H; Macauley J; Lewis AM; Peden K
Vaccine; 2011 Apr; 29(17):3155-61. PubMed ID: 21354480
[TBL] [Abstract][Full Text] [Related]
28. Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.
Chan CY; Tambyah PA
Expert Rev Vaccines; 2012 Jul; 11(7):759-73. PubMed ID: 22913252
[TBL] [Abstract][Full Text] [Related]
29. Development of Vero cell-derived inactivated Japanese encephalitis vaccine.
Sugawara K; Nishiyama K; Ishikawa Y; Abe M; Sonoda K; Komatsu K; Horikawa Y; Takeda K; Honda T; Kuzuhara S; Kino Y; Mizokami H; Mizuno K; Oka T; Honda K
Biologicals; 2002 Dec; 30(4):303-14. PubMed ID: 12421588
[TBL] [Abstract][Full Text] [Related]
30. Influenza vaccines: recent advances in production technologies.
Bardiya N; Bae JH
Appl Microbiol Biotechnol; 2005 May; 67(3):299-305. PubMed ID: 15660212
[TBL] [Abstract][Full Text] [Related]
31. Vaccine manufacture at the time of a pandemic influenza.
Chalumeau HP
Eur J Epidemiol; 1994 Aug; 10(4):487-90. PubMed ID: 7843364
[TBL] [Abstract][Full Text] [Related]
32. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting.
Bull World Health Organ; 1995; 73(4):431-5. PubMed ID: 7554013
[TBL] [Abstract][Full Text] [Related]
33. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
[TBL] [Abstract][Full Text] [Related]
34. Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine.
Lee YH; Jang YH; Seong BL
Virology; 2017 Apr; 504():73-78. PubMed ID: 28157547
[TBL] [Abstract][Full Text] [Related]
35. A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells.
Wen F; Li L; Zhao N; Chiang MJ; Xie H; Cooley J; Webby R; Wang PG; Wan XF
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118117
[TBL] [Abstract][Full Text] [Related]
36. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
[TBL] [Abstract][Full Text] [Related]
37. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response.
Johansson BE; Matthews JT; Kilbourne ED
Vaccine; 1998; 16(9-10):1009-15. PubMed ID: 9682352
[TBL] [Abstract][Full Text] [Related]
38. Development and identification of a new Vero cell-based live attenuated influenza B vaccine by a modified classical reassortment method.
Yang F; Ma L; Zhou J; Wu Y; Gao J; Song S; Geng X; Guo Q; Li Z; Li W; Liao G; Li Y
Expert Rev Vaccines; 2017 Aug; 16(8):855-863. PubMed ID: 28581345
[TBL] [Abstract][Full Text] [Related]
39. Development of high-yield influenza B virus vaccine viruses.
Ping J; Lopes TJ; Neumann G; Kawaoka Y
Proc Natl Acad Sci U S A; 2016 Dec; 113(51):E8296-E8305. PubMed ID: 27930325
[TBL] [Abstract][Full Text] [Related]
40. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE
J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
